Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 7NIH 6OTHER 5NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 47Magnetic Resonance Spectroscopy 38Cyclophosphamide 28Vincristine 22Radiation 19Dexamethasone 19Etoposide 18Cisplatin 18Carboplatin 17Biopsy 17Radiotherapy 16Doxorubicin 13Cytarabine 13daratumumab 12Leucovorin 12Methotrexate 11Gemcitabine 11X-Rays 10Standard of Care 10Platinum 10Docetaxel 10durvalumab 9Rituximab 9Radiotherapy, Intensity-Modulated 9Prednisone 9Practice Guidelines as Topic 9Calcium Dobesilate 91,2-diaminocyclohexaneplatinum II citrate 9merphos 8dexamethasone acetate 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × ALT-803 × 90 days × Clear all
NCT05096663 2026-05-18

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2/3 Active not recruiting
82 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡